Maryam Moradi Binabaj1, Afsane Bahrami2, Majid Khazaei3, Mikhail Ryzhikov4, Gordon A Ferns5, Amir Avan6, Seyed Mahdi Hassanian7. 1. Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran. 3. Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Division of Pulmonary and Critical Care Medicine, Washington University, School of Medicine, Saint Louis, MO, USA. 5. Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK. 6. Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 7. Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: hasanianmehrm@mums.ac.ir.
Abstract
BACKGROUND: The relationship between the expression of cyclin D1 and cancer prognosis and outcomes in different malignancies has not been fully elucidated. AIMS: In the presented meta-analysis, we assessed the association between the expression level of cyclin D1 with overall survival (OS) in several cancers. METHODS: Eligible studies were identified using PubMed, EMBase, Scopus, Web of Sciences and Cochrane Library databases. For the prognostic meta-analysis, study-specific hazard ratios (HRs) of tissue cyclin D1 for survival were obtained. Finally we pooled data derived from one hundred and eight studies comprising 19,224 patients with 10 different cancer types. RESULTS: In the pooled analysis, high expression of cyclin D1 was significantly related to a poor OS with a pooled HR of 1.11 (95% CI: 1.02-1.20, P=0.015; random-effects). Sub-group analysis revealed that high expression of cyclin D1 was related to worse OS of head and neck cancers (HR=2.08, 95% CI: 1.75-2.47; P<0.001), but not in breast (HR=1.033, 95% CI: 0.873-1.223, P= 0.702), gastrointestinal (HR = 1.025, 95% CI:0.824-1.275; P=0.825), bladder (HR=0.937, CI: 0.844-1.041; P=0.225) and in lung cancer patients (HR=1.092, CI: 0.819-1.455; P=0.549). CONCLUSION: Further large, prospective, and well-designed trials are warranted to elucidate the precise clinical importance of cyclin D1 overexpression in the prognosis of cancer patients receiving different treatment regimens.
BACKGROUND: The relationship between the expression of cyclin D1 and cancer prognosis and outcomes in different malignancies has not been fully elucidated. AIMS: In the presented meta-analysis, we assessed the association between the expression level of cyclin D1 with overall survival (OS) in several cancers. METHODS: Eligible studies were identified using PubMed, EMBase, Scopus, Web of Sciences and Cochrane Library databases. For the prognostic meta-analysis, study-specific hazard ratios (HRs) of tissue cyclin D1 for survival were obtained. Finally we pooled data derived from one hundred and eight studies comprising 19,224 patients with 10 different cancer types. RESULTS: In the pooled analysis, high expression of cyclin D1 was significantly related to a poor OS with a pooled HR of 1.11 (95% CI: 1.02-1.20, P=0.015; random-effects). Sub-group analysis revealed that high expression of cyclin D1 was related to worse OS of head and neck cancers (HR=2.08, 95% CI: 1.75-2.47; P<0.001), but not in breast (HR=1.033, 95% CI: 0.873-1.223, P= 0.702), gastrointestinal (HR = 1.025, 95% CI:0.824-1.275; P=0.825), bladder (HR=0.937, CI: 0.844-1.041; P=0.225) and in lung cancerpatients (HR=1.092, CI: 0.819-1.455; P=0.549). CONCLUSION: Further large, prospective, and well-designed trials are warranted to elucidate the precise clinical importance of cyclin D1 overexpression in the prognosis of cancerpatients receiving different treatment regimens.
Authors: Timo Atula; Jaana Hagström; Anttoni Markkanen; Katri Aro; Anna Ray Laury; Antti A Mäkitie; Caj Haglund Journal: Sci Rep Date: 2022-05-30 Impact factor: 4.996
Authors: Anna Kotulak-Chrzaszcz; Agnieszka Rybarczyk; Jakub Klacz; Marcin Matuszewski; Zbigniew Kmiec; Piotr M Wierzbicki Journal: Int J Mol Med Date: 2022-03-10 Impact factor: 4.101